Understanding these dual roles and analyzing which one is acting in each situation is crucial for carefully evaluating the potential use of CXCR3/CXCL9/CXCL10 plasma determination as a predictive biomarker for identifying ICI responders among MM patients. The gene discussed is CXCL9; the disease is Miyoshi myopathy.